AtomVie Global Radiopharma

AtomVie Opens $160M Radiopharma Plant, 10x Capacity in Ontario

Hamilton, Ontario – September 09, 2026 -- AtomVie Global Radiopharma has opened a new 72,300-square-foot production facility at 10 Aeropark Boulevard in Hamilton, Ontario, backed by more than $160 million in investment and marking the largest single-site radiopharmaceutical CDMO facility in North America.

New facility multiplies AtomVie's manufacturing output tenfold

The purpose-built plant increases AtomVie's production capacity by a factor of ten, supporting both low- and high-throughput manufacturing. The site is designed to handle the full lifecycle of radiopharmaceutical production, from early-stage clinical development through commercial-scale manufacturing, with flexible space reserved for future client requirements.

AtomVie Opens $160M Radiopharma Plant, North America's Largest CDMO Site

Hamilton, Ontario – September 09, 2026 -- AtomVie Global Radiopharma has opened a new $160 million manufacturing facility in Hamilton, Ontario, that the company calls the largest single-site radiopharmaceutical CDMO plant in North America.

New 72,300-square-foot plant multiplies manufacturing capacity tenfold

The purpose-built facility at 10 Aeropark Boulevard spans 72,300 square feet and increases AtomVie's manufacturing capacity by more than ten times its previous output. The site is designed to handle low- to high-volume production runs and supports a continuous path from early-stage clinical development through commercial-scale manufacturing.

AtomVie Opens $160M Radiopharma Facility, Largest CDMO Site in North America

Hamilton, ON – September 08, 2026 -- AtomVie Global Radiopharma has opened a 72,300-square-foot manufacturing facility at 10 Aeropark Boulevard in Hamilton, Ontario, representing an investment exceeding $160 million and marking the largest single-site CDMO facility in North America for radiopharmaceutical development.

New site delivers more than tenfold increase in manufacturing capacity

The purpose-built facility supports low-to-high throughput production, enabling AtomVie to scale operations from early clinical development through commercial manufacturing for its partners. The company is targeting a workforce of more than 200 employees by the end of 2026 as the site ramps toward full operational capacity.